Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

OB:AUTO
OB:AUTOMachinery

What Does AutoStore's (OB:AUTO) Profit Growth Amid Falling Sales Reveal About Its Competitive Positioning?

AutoStore Holdings Ltd. recently announced its third quarter 2025 earnings, reporting sales of US$139 million and net income of US$32.2 million, compared to last year’s US$144.2 million and US$31.1 million, respectively. Despite the quarterly improvement in net income, the company’s results for the first nine months of 2025 highlighted significantly lower revenue and profits than the same period in the previous year. With the quarterly net income increase amid declining sales, we’ll now...
NasdaqCM:KRRO
NasdaqCM:KRROBiotechs

Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation

In the past week, Korro Bio announced a significant restructuring aimed at extending its cash runway, including a workforce reduction of approximately 34%, alongside an update on its Phase 1/2a REWRITE clinical trial for KRRO-110 in AATD, which showed acceptable safety but did not meet expected efficacy thresholds. These announcements coincide with the temporary pause of its collaboration with Novo Nordisk and the resignation of its Chief Medical Officer, highlighting a period of transition...
TSE:4684
TSE:4684IT

Does OBIC’s New Share Buyback Boost Capital Efficiency for Investors in TSE:4684?

OBIC Co.,Ltd. recently authorized a share repurchase program, with plans to buy back up to 6,000,000 shares, representing 1.36% of its outstanding share capital excluding treasury stock, at a total cost of ¥30,000 million, valid through March 31, 2026. This move is designed to enhance capital efficiency and introduce flexibility for adapting to evolving business conditions, underscoring a shareholder-focused approach to capital management. Let's explore how the share buyback authorization...
NasdaqGS:IRWD
NasdaqGS:IRWDBiotechs

Ironwood Pharmaceuticals (IRWD): Evaluating Valuation After Q3 Earnings Beat and Linzess Pediatric Approval

Ironwood Pharmaceuticals (IRWD) captured investor attention after reporting a strong beat in its third-quarter 2025 earnings and raising its full-year guidance. The results were fueled by higher-than-expected U.S. sales of Linzess as well as regulatory progress. See our latest analysis for Ironwood Pharmaceuticals. Ironwood’s blowout quarterly earnings and boosted financial guidance sparked a dramatic shift in sentiment, sending the share price up over 120% in the last month alone. While...